Effect of Postmastectomy Radiation Therapy in Node-Positive Breast Cancer


Key Points

  • Postmastectomy radiation therapy was associated with a lower 10-year risk of locoregional recurrence.
  • No difference in 10-year breast cancer–specific or overall survival was observed with postmastectomy radiation therapy.  

In an analysis of data from the Breast International Group (BIG) 02-98 trial reported in the International Journal of Radiation Oncology*Biology*Physics, Zeidan et al found that postmastectomy radiation therapy (PMRT) vs no PMRT was associated with significantly reduced risk of locoregional recurrence in women with T1-T2 breast cancer and one to three positive nodes. PMRT was not associated with differences in 10-year cancer-specific or overall survival.

Study Details

In the BIG 02-98 trial, 2,887 patients with invasive breast cancer (clinical stage T1–3) who underwent surgical resection (mastectomy or breast-conserving surgery) with negative margins and had at least 1 positive axillary lymph node were randomized to receive adjuvant anthracycline with or without taxane chemotherapy. PMRT was performed according to institutional preference.

The current analysis assessed 10-year outcomes among 684 patients with T1–T2 disease and 1 to 3 positive lymph nodes who underwent mastectomy and axillary nodal dissection, including 337 (49%) who received PMRT. The primary outcome of interest was locoregional recurrence.

10-Year Outcomes

At 10 years, the risk of locoregional recurrence was 2.5% in the PMRT group vs 6.5% in the no-PMRT group (hazard ratio [HR] = 0.29, P = .005).  Among patients who received adjuvant chemotherapy with no taxane, the 10-year locoregional recurrence rate was 3.4% in the PMRT group vs 9.1% in the no-PMRT group (HR = 0.20, P = .02); among those receiving taxane-based adjuvant therapy, rates were 2.0% vs 5.3% (HR = 0.37, P = .08).

The 10-year distant recurrence-free survival rate was 77.3% vs 75.9% (HR = 1.10, P =.59). No significant differences between the PMRT group and the no-PMRT groups were observed for 10-year breast cancer–specific survival (84.3% vs 83.9%, HR  = 0.98, P = .91) or 10-year overall survival (81.7% vs 78.3%, HR = 0.87, P = .47).

The investigators concluded, “Our analysis of the BIG 02-98 trial shows excellent outcomes in women with T1–2 tumors and [one to three] positive lymph nodes found in axillary dissection. Although PMRT improved [locoregional recurrence] in this cohort, the number of events remained low at 10 years. In all groups, 10-year rates of [locoregional recurrence] were relatively low compared with historical studies. As such, the use of PMRT in women with [one to three] positive nodes should be tailored to individual patient risks.”

The study was funded by Sanofi-Aventis and by grants from the National Health and Medical Research Council to Breast Cancer Trials Australia & New Zealand.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.